Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 20/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 20/20 | 1.00 |
| ▸ | IGF1R | P08069 | 14/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.85 |
| ▸ | PLK4 | O00444 | 1/20 | 0.85 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.85 |
| ▸ | JAK2 | O60674 | 1/20 | 0.85 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.85 |
| ▸ | ABL1 | P00519 | 1/20 | 0.85 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.85 |
| ▸ | PRKCG | P05129 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.85 |
| ▸ | FYN | P06241 | 1/20 | 0.85 |
| ▸ | CSF1R | P07333 | 1/20 | 0.85 |
| ▸ | LYN | P07948 | 1/20 | 0.85 |
| ▸ | RET | P07949 | 1/20 | 0.85 |
| ▸ | MET | P08581 | 1/20 | 0.85 |
| ▸ | ROS1 | P08922 | 1/20 | 0.85 |
| ▸ | KIT | P10721 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21759430 | 0.96 | INSR (0.92) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL26275691 | 0.93 | INSR (0.88) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL26271852 | 0.93 | INSR (0.87) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL30170709 | 0.93 | INSR (0.86) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL26358559 | 0.93 | INSR (0.88) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL25397352 | 0.93 | INSR (0.86) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL23635199 | 0.92 | INSR (0.87) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL25272952 | 0.92 | INSR (0.87) | INSRALKIGF1RAURKAAURKB | |
| Entrectinib SCHEMBL3512601 | 0.92 | INSR (1.00) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL30170811 | 0.92 | INSR (0.85) | INSRALKIGF1RAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170356918-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | IGNYTA, INC. (US) | 2017-12-14 | — | — | US | claimed |
| EP-3227686-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | Ignyta, Inc. (US) | 2017-10-11 | — | — | EP | claimed |
| EP-3227276-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROBLASTOMA | Ignyta, Inc. (US) | 2017-10-11 | — | — | EP | claimed |
| EP-3107541-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | Ignyta, Inc. (US) | 2016-12-28 | — | — | EP | claimed |
| EP-2176231-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-10-19 | — | — | EP | claimed |
| WO-2016089760-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROBLASTOMA | IGNYTA, INC. (US) | 2016-06-09 | — | — | WO | claimed |
| WO-2016089853-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | IGNYTA, INC. (US) | 2016-06-09 | — | — | WO | claimed |
| US-20150283132-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | IGNYTA, INC. | 2015-10-08 | — | — | US | claimed |
| WO-2015124697-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | IGNYTA, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-9102662-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-11 | — | — | US | claimed |
| US-20150057292-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-26 | — | — | US | claimed |
| US-8299057-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-30 | — | — | US | claimed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | claimed |
| EP-2176231-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2010-04-21 | — | — | EP | claimed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | claimed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-2176231-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | INSR 387/4885ALK 401/4885IGF1R 188/4885 |
| US-20150283132-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | ROS1, KRAS, NOX1 | INSR 303/4885ALK 337/4885IGF1R 72/4885 |
| US-20170356918-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | TP53, BRCA1, MKI67 | INSR 3857/4885ALK 277/4885IGF1R 541/4885 |
| US-20150057292-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | INSR 433/4885ALK 397/4885IGF1R 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.